Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maho Murata

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Current Treatment Options in Oncology|March 21, 2022
Nectin-4: a Novel Therapeutic Target for Skin CancersHiroki Hashimoto, Yuka Tanaka, Maho Murata, et al.
The Kobe Journal of Medical Sciences|March 5, 2009
Expression of beta-catenin and integrin-linked kinase in the mouse sciatic nerveJunichiro Takeuchi, Yasuyuki Shibuya, Maho Murata, et al.
Biomedicines|April 3, 2021
Nectin Cell Adhesion Molecule 4 (NECTIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target?Yuka Tanaka, Maho Murata, Yoshinao Oda, et al.
BMC Medical Ethics|September 12, 2022
Current status of umbilical cord blood storage and provision to private biobanks by institutions handling childbirth in JapanMaho Murata, Kenichiro Kawabe, Taichi Hatta, et al.
Scientific Reports|March 8, 2022
Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcomaYuka Tanaka, Maho Murata, Keiko Tanegashima, et al.
International Journal of Molecular Sciences|August 23, 2020
NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic TargetMaho Murata, Takamichi Ito, Yuka Tanaka, et al.
International Journal of Molecular Sciences|January 22, 2021
NECTIN4: A Novel Therapeutic Target for MelanomaYuka Tanaka, Maho Murata, Che-Hung Shen, et al.
Journal of Clinical Medicine|February 29, 2020
OVOL2-Mediated ZEB1 Downregulation May Prevent Promotion of Actinic Keratosis to Cutaneous Squamous Cell CarcinomaMaho Murata, Takamichi Ito, Yuka Tanaka, et al.
The Kobe Journal of Medical Sciences|November 11, 2010
A case of malignant melanoma of the oral cavity alive with liver metastasis for a long period with administration of a biologic response modifier, OK432Masahiro Umeda, Maho Murata, Hiroaki Suzuki, et al.
Current Treatment Options in Oncology|February 9, 2021
BRAF Heterogeneity in MelanomaTakamichi Ito, Yuka Tanaka, Maho Murata, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Current Treatment Options in Oncology|March 21, 2022
Nectin-4: a Novel Therapeutic Target for Skin CancersHiroki Hashimoto, Yuka Tanaka, Maho Murata, et al.
The Kobe Journal of Medical Sciences|March 5, 2009
Expression of beta-catenin and integrin-linked kinase in the mouse sciatic nerveJunichiro Takeuchi, Yasuyuki Shibuya, Maho Murata, et al.
Biomedicines|April 3, 2021
Nectin Cell Adhesion Molecule 4 (NECTIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target?Yuka Tanaka, Maho Murata, Yoshinao Oda, et al.
BMC Medical Ethics|September 12, 2022
Current status of umbilical cord blood storage and provision to private biobanks by institutions handling childbirth in JapanMaho Murata, Kenichiro Kawabe, Taichi Hatta, et al.
Scientific Reports|March 8, 2022
Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcomaYuka Tanaka, Maho Murata, Keiko Tanegashima, et al.
International Journal of Molecular Sciences|August 23, 2020
NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic TargetMaho Murata, Takamichi Ito, Yuka Tanaka, et al.
International Journal of Molecular Sciences|January 22, 2021
NECTIN4: A Novel Therapeutic Target for MelanomaYuka Tanaka, Maho Murata, Che-Hung Shen, et al.
Journal of Clinical Medicine|February 29, 2020
OVOL2-Mediated ZEB1 Downregulation May Prevent Promotion of Actinic Keratosis to Cutaneous Squamous Cell CarcinomaMaho Murata, Takamichi Ito, Yuka Tanaka, et al.
The Kobe Journal of Medical Sciences|November 11, 2010
A case of malignant melanoma of the oral cavity alive with liver metastasis for a long period with administration of a biologic response modifier, OK432Masahiro Umeda, Maho Murata, Hiroaki Suzuki, et al.
Current Treatment Options in Oncology|February 9, 2021
BRAF Heterogeneity in MelanomaTakamichi Ito, Yuka Tanaka, Maho Murata, et al.
Pageof 5